EUCTR2008-003421-17-CZ进行中（未招募）1 期
Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with paroxetine (20 mg/day with potential progressive blinded adjustment to 40 mg/day) as validator, 3-arm parallel groups, international multicenter study.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Out-patients of both genders, - Aged over 18 years, - Fulfilling DSM-IV-TR criteria for Generalized Anxiety Disorder.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Women of childbearing potential without effective contraception, - Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than GAD, - Any clinically relevant abnormality detected during the physical examination, ECG or laboratory tests likely to interfere with the study conduct or evaluations.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder.Generalized anxiety disorderMedDRA version: 13.1Level: LLTClassification code 10018105Term: Generalized anxiety disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2009-013789-17-FIInstitut de Recherches Internationales Servier390
进行中（未招募）
不适用
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depressive episode. An 8-week randomised, double-blind, controlled, parallel groups study followed by a double-blind extension treatment period up to 1 year.EUCTR2005-004881-17-ATInstitut de Recherches Internationales Servier300
进行中（未招募）
不适用
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depressive episode. An 8-week randomised, double-blind, controlled, parallel groups study followed by a double-blind extension treatment period up to 1 year.EUCTR2005-004881-17-FIInstitut de Recherches Internationales Servier300
进行中（未招募）
1 期
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depressive episode. An 8-week randomised, double-blind, controlled, parallel groups study followed by a double-blind extension treatment period up to 1 year.Major depressive episode in the framework of bipolar disorderMedDRA version: 7.0Level: PTClassification code 10004939EUCTR2005-004881-17-DKInstitut de Recherches Internationales Servier300
进行中（未招募）
不适用
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depressive episode. An 8-week randomised, double-blind, controlled, parallel groups study followed by a double-blind extension treatment period up to 1 year.EUCTR2005-004881-17-NLInstitut de Recherches Internationales Servier300